Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
By
Jessica Wright
26 February 2019 | 6 min read
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
By
Jessica Wright
24 May 2016 | 6 min read
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
By
Nicholette Zeliadt
17 February 2015 | 5 min read
Explore more from The Transmitter
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
By
Claudia López Lloreda
2 October 2025 | 6 min read
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
By
Calli McMurray
2 October 2025 | 10 min read
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
By
Brendan Borrell
1 October 2025 | 11 min read